Beam Therapeutics is trading 4.4% lower at $24.79 as broader market and risk-off conditions weigh on U.S. equities. - The Nasdaq Composite is down 1.03%, while renewed oil-driven inflation concerns are lifting Treasury yields. - No fresh company-specific announcement clearly explains the September 23 decline. - Recent coverage of a shareholder-fraud investigation concerns the September 8 BEAM-302 data release, not a newly reported event; biotechnology had rallied during the prior session.